Dewpoint Therapeutics nominates condensate modulator as development candidate for Wnt-driven cancers

Oct. 29, 2024

Dewpoint Therapeutics Inc. has nominated its first development candidate, DPTX-3186, an orally administered small-molecule condensate modulator inhibiting the oncogenic function of β-catenin, for the treatment of Wnt-driven cancers.

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for Nov. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 13, 2025.

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...